Pfizer doubles down on AI partnership with antibody-drug conjugate deal

Pfizer is expanding its collaboration with the start-up PostEra, which applies artificial intelligence to medicinal chemistry. The pharmaceutical giant will pay the smaller firm up to $350 million to use software models to design new small molecules as well as antibody-drug conjugates, or ADCs.